. Author manuscript; available in PMC: 2008 Oct 18.

Published in final edited form as: Cancer Lett. 2007 Jul 9;256(1):101–111. doi: 10.1016/j.canlet.2007.06.003

Table 4.

Ceramide levels ^* of patients with or without lymphovascular invasion

Subspecies	Without Lymphovascular Invasion (n=26)	With Lymphovascular Invasion (n=14)	P^**
Total Ceramide
Normal	258±193	328±317	.39
Tumor	380±299	382±321	.98
C₁₆-ceramide
Normal	101±91.4	99.9±106	.98
Tumor	183±140	144±112	.38
C₁₈-ceramide
Normal	25.0±18.1	26.5±19.7	.81
Tumor	14.6±10.7	8.49±5.94	.05
C_18:1-ceramide
Normal	8.95±10.7	8.87±9.61	.98
Tumor	7.33±7.59	6.13±6.02	.61
C₂₄-ceramide
Normal	42.3±67.3	60.7±64.9	.41
Tumor	58.0±74.1	87.3±87.0	.27
C_24:1-ceramide
Normal	60.0±43.9	99.2±108	.11
Tumor	87.2±90.3	112±111	.45

pmol/1mg protein, mean+SD

^**

Unpaired T Test